Literature DB >> 18455933

Ocular features of CHARGE syndrome.

Karen McMain1, Kim Blake, Isabel Smith, Judy Johnson, Ellen Wood, Francois Tremblay, Johane Robitaille.   

Abstract

PURPOSE: To detail the presence and severity of ocular and cranial nerve abnormalities found in individuals with CHARGE syndrome in a distinct geographic area.
METHODS: Nine individuals with CHARGE syndrome from Maritime Canada identified from a Canadian database were prospectively examined. Structural and sensorial defects associated with functional visual deficits were defined with ophthalmic and neurological evaluation.
RESULTS: Consistent with current diagnostic criteria and the literature, colobomas were the major ophthalmic manifestation. These were typically bilateral chorioretinal colobomas involving the optic nerve. All subjects had bilateral severe sensorineural deafness (cranial nerve VIII), and 8 of 9 (89%) had facial nerve (cranial nerve VII) involvement (7 of 9 had unilateral involvement; 1 of 9 had bilateral involvement). Unique to this group of participants were the findings of anisometropia in 8 of the 9 (89%) patients, severe myopic astigmatism in 13 of the 18 eyes (72%), and limited elevation in adduction in 3 of 9 (33%) participants. Associated findings were strabismus, cataracts, microcornea, keratopathy, staphyloma, reduced stereopsis, superior visual field defects, and reduced visual acuity.
CONCLUSIONS: The presence of coloboma plus another CHARGE feature warrants further investigation, including genetic screening for the CHD7 gene. Early recognition and management of sensory problems (visual, auditory, and vestibular) are crucial to ensure best psychomotor and cognitive development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18455933     DOI: 10.1016/j.jaapos.2008.02.009

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  8 in total

1.  Visual electrophysiological findings in CHARGE syndrome with bilateral colobomas: a case report.

Authors:  R Hamilton; P Gonzalez; J Dudgeon; H Mactier
Journal:  Doc Ophthalmol       Date:  2010-03-09       Impact factor: 2.379

Review 2.  Genetics of syndromic ocular coloboma: CHARGE and COACH syndromes.

Authors:  Aman George; Tiziana Cogliati; Brian P Brooks
Journal:  Exp Eye Res       Date:  2020-02-04       Impact factor: 3.467

3.  Cerebellar vermis hypoplasia in CHARGE syndrome: clinical and molecular characterization of 18 unrelated Korean patients.

Authors:  Young Bae Sohn; Jung Min Ko; Choong Ho Shin; Sei Won Yang; Jong-Hee Chae; Kyung-A Lee
Journal:  J Hum Genet       Date:  2015-11-05       Impact factor: 3.172

Review 4.  Ocular involvement in primary immunodeficiency diseases.

Authors:  Sima Hosseinverdi; Hassan Hashemi; Asghar Aghamohammadi; Hans D Ochs; Nima Rezaei
Journal:  J Clin Immunol       Date:  2013-11-30       Impact factor: 8.542

Review 5.  Guidelines in CHARGE syndrome and the missing link: Cranial imaging.

Authors:  Christa M de Geus; Rolien H Free; Berit M Verbist; Deborah A Sival; Kim D Blake; Linda C Meiners; Conny M A van Ravenswaaij-Arts
Journal:  Am J Med Genet C Semin Med Genet       Date:  2017-11-23       Impact factor: 3.908

6.  CHARGE Syndrome Associated with Angle Closure despite High Myopia: A Case Report with Structural Suggestion.

Authors:  Saki Dote; Shunsuke Nakakura; Hirotaka Tanabe; Etsuko Terao; Yuki Nagata; Hitoshi Tabuchi; Yoshiaki Kiuchi
Journal:  Case Rep Ophthalmol       Date:  2020-01-09

Review 7.  Eyes on CHARGE syndrome: Roles of CHD7 in ocular development.

Authors:  Laura A Krueger; Ann C Morris
Journal:  Front Cell Dev Biol       Date:  2022-09-08

8.  Visual Function and Ophthalmological Findings in CHARGE Syndrome: Revision of Literature, Definition of a New Clinical Spectrum and Genotype Phenotype Correlation.

Authors:  Roberta Onesimo; Daniela Ricci; Cristiana Agazzi; Simona Leone; Maria Petrianni; Lorenzo Orazi; Filippo Amore; Annabella Salerni; Chiara Leoni; Daniela Chieffo; Marco Tartaglia; Eugenio Mercuri; Giuseppe Zampino
Journal:  Genes (Basel)       Date:  2021-06-25       Impact factor: 4.096

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.